Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 1-4, March 2007

The true impact of new targeted therapies for AML

  • Jacob M. Rowe, MD (Director)

      Affiliations

    • Corresponding Author InformationTel.: +972 4 854 2541; Fax: +972 4 854 2343.

Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, 31096 Haifa, Israel

No abstract is available. To read the body of this article, please view the Full Text online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(06)00082-X

doi:10.1016/j.beha.2006.11.003

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 1-4, March 2007

Article Tools

* Image Usage & Resolution